If PTO is to achieve its goal of fostering U.S. involvement and leadership in standards development in the most important technological areas, then policies and regulatory action must accord with private property rights and free markets.  Otherwise, the initiative is destined to fall short of fostering U.S. innovation, standards development, SEPs and licensing.

Given the well-documented destructive history of price controls and the law’s expansion of government power over our health-care system, we, the undersigned organizations, strongly urge Congress to repeal the prescription drug prices controls found within the Inflation Reduction Act.

The International Trade Commission’s thorough investigation provides the U.S. Trade Representative no basis for expanding the TRIPS waiver to COVID diagnostics and therapeutics.

CPR strongly commends the Waters of the United States provision in the U.S. House’s FY24 Energy and Water appropriations. H.R. 4394 blocks EPA’s latest attempt at regulatory takings of private land.

This award-winning film gave Capitol Hill attendees a focus on ingenuity, property rights, and the stakes of global leadership in emerging technologies. CPR, the Inventor's Project and Tea Party Patriots Action cosponsored, Rep. Bill Posey gave remarks about U.S.-China competitiveness and innovation’s and IP's critical roles.

The U.S. Chamber Global Innovation Policy Center’s IP principles describe how "a renewed and principled approach to intellectual property is key to unlocking America’s full innovative and creative potential in the 21st century.” CPR’s James Edwards ranks among the signatories.

S. 2140 would fully invalidate all judicially created exceptions to patent eligibility. It would restore the congressionally intentional breadth of the section 101 threshold question as to patent-eligible subject matter, including of a “useful process.”

CPR cautions the agency against new changes which could have deleterious effects on patients and give competitors like China an edge in the technology sphere.

These “reasonable pricing” requirements would apply to marketable drug, biologic, or other medical technology that stems from federal research funding from the Centers for Disease Control (CDC) and BARDA. These strictures are virtually guaranteed to reduce innovation and fail to achieve the stated goal.

The Senate HELP Committee’s Pandemic and All-Hazards Preparedness Act reauthorization contains “reasonable pricing” provisions of grave concern. These would repeat the National Institutes of Health’s tried-and-failed experience of the 1990s.

The PREVAIL Act would secure private property rights to inventions and give quiet title, which is crucial for commercialization and investment. That will boost the United States’s competitive edge in emerging technologies important to our economic and national security.

To be successful, any rule must ensure that patent owners have quiet title to their intellectual property, the exclusivity the U.S. Constitution promises to secure, and the ability to enforce their legal rights against patent infringers.

IP rights only work when they can be enforced through judicial process with meaningful remedy. The appellate ruling undermines confidence in the judicial process and harms innovators that confront willful infringement committed by larger competitors.

PTAB endangers America’s inventors whose commercial success is vital to our global leadership in innovation. Beleaguered inventors face tremendous threats, due to PTAB and its most frequent users, Big Tech and Chinese national champions.

CPR strongly supports Centripetal Networks’s request for rehearing and POP review of the decision instituting IPR. Centripetal won in Article III court. Palo Alto is gaming the system to get leverage in separate litigation involving different patents.

Amici urge the Supreme Court to adopt a "continuous surface connection" standard in WOTUS wetlands cases under the Clean Water Act. This will reduce regulatory takings and Fifth Amendment violations.

DOJ's draft statement on standards-essential patents falls short of achieving the proper balance, neutrality, and respect for both innovators and implementers in their complementary roles related to innovation, SEPs, and licensing. 

H.R. 5874, the Restoring America’s Leadership in Innovation Act, would strengthen private property rights in one’s inventions and discoveries. The bill would go a long way toward reversing the antipatent onslaught of recent years. RALIA would counter the sustained assault by courts, Congress, the Administrative State, and patent-infringer interests.

This webinar, hosted by Conservatives for Property Rights, highlights how ownership rights relate to private property of every type. Keynote Speaker: Rep. Dan Newhouse (R-Wash.), House Chairman, Congressional Western Caucus.